The wide-scale prevalence of preclinical models exemplifying PARP inhibitors that show clinical activity in ovarian cancer, breast and prostate cancer as single agents, sensitize tumor cells to Top1 poisons in vitro and in vivo propelled combining PARP inhibitors with Top1 poison in the clinics. This evidence concerns the gene PARP1 and ovarian cancer.